Journal of cancer research & therapy最新文献

{"title":"Capecitabine induced hypertriglyceridaemia: An underreported and potentially severe side effect","authors":"S. Tabchi, K. Joseph","doi":"10.14312/2052-4994.2014-11","DOIUrl":"https://doi.org/10.14312/2052-4994.2014-11","url":null,"abstract":"A 57 year-old-woman, with no previous history of dyslipedemia, developed severe hypertriglyceridemia while being treated with capecitabine for metastatic breast cancer. Capecitabine was not discontinued and serum triglyceride levels were normalized after 4 weeks of treatment with fenofibrate. Capecitabine induced hypertriglyceridemia, as a rare drugrelated side effect, seems to be often overlooked by clinicians.","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"5 1","pages":"82-83"},"PeriodicalIF":0.0,"publicationDate":"2014-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80109575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of chronic liver disease using a multivariate analysis of associated risk factors in patients with hepatocellular carcinoma treated with transarterial chemoembolization","authors":"P. Farshid, Babak Bazrafshan, Alireza Azizi, E. Mbalisike, T. Vogl","doi":"10.14312/2052-4994.2014-10","DOIUrl":"https://doi.org/10.14312/2052-4994.2014-10","url":null,"abstract":"Purpose: To evaluate the effect of chronic liver disease (CLD) in a multivariate analysis of associated risk factors in patients with hepatocellular carcinoma (HCC) using transarterial chemoembolization (TACE). Materials and methods: A total of 145 patients with HCC (99 men, 46 women; mean age: 63 years ±8.1; age range: 46-84 years) underwent 598 TACE procedures. The presence of CLD, number and location of lesions, tumor size, Child-Pugh score, vascularity, portal involvement and alpha fetoprotein value were analyzed using the multivariate regression model. Cox regression was used for survival analysis. Results: The median survival time was 26.7 months, and 78.6% of all treated lesions showed tumor responses. The presence of CLD (OR 2.12, P=0.004), Child-Pugh score B (OR 2.24, P=0.002), alpha fetoprotein >100ng/dl (OR 1.18, P 5cm (OR 4.12, P=0.002) and hypervascularity (OR 7.94, P=0.003) were significant effective factors for a local response when analyzed using a multivariate logistic model. Multivariate survival analysis using Cox's regression model during the median follow-up period of 25 months (range: 1-42 months) demonstrated a significant difference in survival rates (P values 5cm and hypervascularity statistically led to a significant effect in tumor response in HCC patients treated with TACE. Patient gender, location of lesion and involvement of portal vein showed no significant difference in response.","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"39 1","pages":"74-81"},"PeriodicalIF":0.0,"publicationDate":"2014-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88470189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Decitabine is more cost effective than cytarabine and daunorubicin in elderly acute myeloid leukemia patients","authors":"N. Batty, Yong Yin, M. Wetzler","doi":"10.14312/2052-4994.2014-9","DOIUrl":"https://doi.org/10.14312/2052-4994.2014-9","url":null,"abstract":"Introduction: Decitabine is not approved in the United States (US) for acute myeloid leukemia (AML) because it did not improve overall survival compared with standard conventional induction treatment with cytarabine and daunorubicin (AD). We asked what would be the cost effectiveness of decitabine versus AD in AML patients older than 60 years of age. Methods: A semi-Markov model compiling survival and cost data was used based on survival probabilities from the literature. Data accounted for re-induction therapy with idarubicin, fludarabine, cytarabine and granulocyte colonystimulating factor and consolidation therapy with high-dose cytarabine (HiDAC) but not for stem cell transplantation. The assumption-based model considered a maximum of four cycles of HiDAC and continuing decitabine until loss of benefit. Results: Assuming 1,000 patients for each treatment arm in a semi-Markov model over one year time horizon, the qualityadjusted life year (QALY) for AD vs. decitabine were 0.47 and 0.61. The percentage survival for AD and decitabine were 45.2% and 50.5%. Their costs were $168,863 and $108,084. The incremental cost-effectiveness ratio was -$60,779/0.14 =-$433,756 per QALY. By sensitivity analysis, decitabine was superior to AD in all parameters. Conclusion: Decitabine is a more cost-effective therapy for patients older than 60 years of age than AD. While cost effectiveness is certainly important, decitabine may be arguably considered for elderly newly diagnosed AML patients given the economic pressures in the US health system; however, this is not a criterion for drug approval.","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"369 1","pages":"68-73"},"PeriodicalIF":0.0,"publicationDate":"2014-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77335136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Original researchTop Antitumor activity of Papua’s Myrmecodia pendans in human oral tongue squamous cell carcinoma cell line through induction of cyclin-dependent kinase inhibitor p27Kip1 and suppression of cyclin E","authors":"M. Supriatno","doi":"10.14312/2052-4994.2014-7","DOIUrl":"https://doi.org/10.14312/2052-4994.2014-7","url":null,"abstract":"Oral tongue squamous cell carcinoma (OTSCC) is one of the most common cancers encountered in Indonesia, due to the prevalent habits of tobacco chewing, alcohol drinking and smoking. Oral tongue cancer is characterized by a high degree of local invasion and a high rate of metastasis to the cervical lymph nodes. Interestingly, treatment options for this cancer are limited. The aim of this study was to examine the antitumor activity of Papua’s Myrmecodia pendans (ant nest plant) in a human oral tongue squamous cell carcinoma cell line (B88) and to explore the possible mechanism in it. In the present study, B88 cells were treated with various concentration of ethanol extract of Papua’s M. pendans. The results revealed that B88 cells treated with Papua’s M. pendans were remarkable suppressed in cell growth and cell invasion, and had a significant induction of apoptosis characterized by an increase in activation of caspase-3 and-9. Furthermore, up-regulation of p27Kip1 and down-regulation of cyclin E protein was detected in B88 cells treated with Papua’s M. pendans. These results indicated that Papua’s M. pendans exhibited a high potential antitumor activity in human oral tongue squamous cell carcinoma through induction of p27Kip1 and suppression of cycline E.","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"8 1","pages":"48-53"},"PeriodicalIF":0.0,"publicationDate":"2014-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84799912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gastrointestinal stromal tumour: From the clinic to the molecules","authors":"I. Hapkova, F. Bernex, Barbara Pds, J. Veselý","doi":"10.14312/2052-4994.2014-8","DOIUrl":"https://doi.org/10.14312/2052-4994.2014-8","url":null,"abstract":"GastroIntestional stromal tumours (GISTs), the most frequent sarcoma in the gastro-intestinal (GI) tract, are highly resistant to conventional chemotherapy and radiotherapy. These tumours have activating mutations in two closely related genes, KIT (75-80%) or/and PDGFRA (5-10%). Targeting these mutated activated proteins with imatinib mesylate has proven efficient in the treatment of GISTs. The median survival after diagnosis of GIST increased from 1.5 to 4.8 years with imatinib treatment. However, resistance to imatinib eventually develops and new-targeted therapies are needed. This paper reviews the medical, clinical and pathological aspects of GISTs based on latest research in human cell lines and animal models.","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"76 1","pages":"54-67"},"PeriodicalIF":0.0,"publicationDate":"2014-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88211835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of Streptococcus bovis infections at a monographic oncological centre","authors":"Lozano Tg, Pilar Pérez Ballestero, Eduardo Aznar Oroval, González Ja","doi":"10.14312/2052-4994.2014-E1","DOIUrl":"https://doi.org/10.14312/2052-4994.2014-E1","url":null,"abstract":"The complex is divided into two subtypes based on biochemical properties: positive mannitol fermentation (biotype I) including S. gallolyticus (S. gallolyticus subsp. gallolyticus and S. gallolyticus subsp. macedonicus), mannitol negative and s-glucuronidase negative (biotype II/ 1), which includes more species (S. infantarius subsp. coli and S. lutetiensis) and mannitol negative and s-glucuronidase positive (biotype II/ 2), with a single species called S. gallolyticus subsp. pasteurianus.","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"30 1","pages":"34-35"},"PeriodicalIF":0.0,"publicationDate":"2014-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74840166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Usefulness of the Glasgow prognostic score for predicting survival in patients with resected non-small cell lung cancer","authors":"M. Tomita, T. Ayabe, Eiichi Chosa, K. Nakamura","doi":"10.14312/2052-4994.2014-5","DOIUrl":"https://doi.org/10.14312/2052-4994.2014-5","url":null,"abstract":"Background: Few studies have investigated whether the Glasgow prognostic score (GPS), an inflammation based prognostic score, is useful for postoperative prognosis of non-small cell lung cancer (NSCLC). Materials and methods: Two hundred and eighty nine consecutive patients of resected NSCLC with a follow-up period more than 5 years were enrolled. GPS was calculated on the basis of admission data as follows: patients with elevated C-reactive protein level (1.0 mg/dL) and hypoalbuminemia (3.5 g/dL) were assigned to GPS 2. Patients with one or no abnormal value were assigned to GPS 1 or GPS 0. Results: Study patients were allocated as follows: 244 (84.44 %) to GPS 0, 28 (9.69 %) to GPS 1, and 16 (5.54 %) to GPS 2. The prognosis of the patients with GPS 2 was significantly poorer. Multivariate logistic analysis identified age, gender, pT status, pN status, serum CEA level and GPS were found to be independent prognostic variables. Conclusions: Preoperative GPS, especially GPS 2, may be useful for postoperative prognosis of patients with NSCLC.","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"53 1","pages":"36-39"},"PeriodicalIF":0.0,"publicationDate":"2014-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80405423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adjuvant concurrent docetaxel, epirubicin and cyclophosphamide chemotherapy in breast cancer: The TEC regimen. A retrospective analysis","authors":"S. Galdy, D. Zenoni, A. Galmozzi, C. Mauri, S. Cazzaniga","doi":"10.14312/2052-4994.2014-6","DOIUrl":"https://doi.org/10.14312/2052-4994.2014-6","url":null,"abstract":"Background: The use of taxanes and anthracyclines in the adjuvant treatment of primary breast cancer is well established, with benefit in both disease free survival (DFS) and overall survival (OS). Several studies demonstrated that the addition of taxanes to anthracycline-based chemotherapy improves the outcome in either concurrent or sequential schedule. Nowadays, the TAC regimen (docetaxel, doxorubicin and cyclophosphamide) is a standard treatment in both node-positive and high-risk node-negative early breast cancer. Doxorubicin and epirubicin are equivalent, but at similar doses epirubicin appears to have a better side effects profile than doxorubicin in terms of myelosuppression and cardiotoxicity. We conducted a retrospective study to establish the role of TEC (epirubicin) regimen in adjuvant setting. Methods: Preor post-menopausal women, with stage I-III breast cancer, PS ECOG 0-2 and normal left ventricular ejection fraction, were eligible. TEC chemotherapy at median doses of docetaxel 75 mg/m2, epirubicin 60 mg/m2 and cyclophosphamide 500 mg/m2 was administered IV on day 1 every three weeks for 6 cycles. The primary endpoint was toxicity; secondary endpoints were DFS and OS. Results: Thirty-three consecutive female patients were retrospectively enrolled. The median age was 57 years old. Eighty eight percentage of patients completed the treatment plan. In 21.2% of cases a dose reduction was performed and these patients needed a chemotherapy interval prolongation. The main side effects were neutropenia G3-4 (21.2%; 95% CI, 9.8-37.5), allergic reaction G3 to docetaxel (6.1%; 95% CI, 1.0-18.6) and febrile neutropenia (3.0%; 95% CI, 0.1-14.0), while cardiotoxicity was absent (95% CI, 0-8.7%). Globally, the percentage of any other severe side effect was very low and no one toxic death was seen. The 3-year DFS and OS were 89.9% (95% CI, 79.0-100) and 93.8% (95% CI, 85.6-100), respectively. Conclusions: As compared to TAC treatment, TEC regimen with epirubicin 60 mg/m2 is feasible and well tolerated adjuvant chemotherapy in breast cancer, with acceptable and manageable toxicity.","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"1 1","pages":"40-47"},"PeriodicalIF":0.0,"publicationDate":"2014-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87077920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prophylactic bundle for radiation-induced oral mucositis in oral or oropharyngeal cancer patients","authors":"Y. Kawashita, S. Hayashida, M. Funahara, M. Umeda, Toshiyuki Saito","doi":"10.14312/2052-4994.2014-2","DOIUrl":"https://doi.org/10.14312/2052-4994.2014-2","url":null,"abstract":"","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"113 1","pages":"9-13"},"PeriodicalIF":0.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86610958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and prognostic significance of plasma fibrinogen in lung cancer","authors":"Chen Ys, Zeng Dh, Li Hr, Wu Yl, X. Lin, Xu Nl, M. Lin","doi":"10.14312/2052-4994.2014-3","DOIUrl":"https://doi.org/10.14312/2052-4994.2014-3","url":null,"abstract":"Objectives: Hyperfibrinogenemia is a common problem associated with various carcinomas. The recent studies have shown that high plasma fibrinogen concentration is associated with invasion, growth and metastases of cancer. Furthermore, the recent studies focus on the prognostic significance of fibrinogen in the patients with advanced NSCLC (stage IIIB -IV). However, the prognostic significance of the plasma fibrinogen levels in early stage NSCLC patients (stage I -IIIA) still remains unclear. In addition, it remains unclear whether or not chemotherapy-induced changes in fibrinogen level relate to the prognosis. The aims of this study were to 1) further explore the relationship between the plasma fibrinogen concentration and the stage and metastases of lung cancer 2) evaluate the prognostic significance of the basal plasma fibrinogen level in patients with lung cancer 3) explore the prognostic value of the change in fibrinogen levels between pre and post-chemotherapy. Methods: In this retrospective study, the data from 370 patients with lung cancer were enrolled into this study. The plasma fibrinogen levels were compared with the clinical and prognostic significance of lung cancer. The association between the plasma fibrinogen level and clinical-prognostic characteristics were analyzed using SPSS 17.0 software. Results: 1) The median pre-treatment plasma fibrinogen levels were 4.20g/L. Pre-treatment plasma fibrinogen levels correlated significantly with gender (p  0.013). A higher plasma fibrinogen concentration was associated with squamous cell carcinoma versus adenocarcinoma (4.831.50 g/L versus 4.151.30 g/L; P0.001), there was a significant association between plasma fibrinogen level and metastases of lung cancer, pointing a higher plasma fibrinogen level in lymph nodes or distant organ metastases (p  0.001). 2) Patients with low plasma fibrinogen concentration demonstrates higher overall survival compared with those with high plasma fibrinogen concentration (median, 19 months versus 35 months; P 0.001). In addition, a similar result was observed in 194 early stage NSCLC (stage I -IIIA) (P 0.001). Univariate and multivariate analysis revealed that higher levels of fibrinogen (FIB4.20 g/L), age, distant metastases and pathological types were positively associated with shorter overall survival (OS). 3) In addition, there was a significant link between the elevation by more than 15% in the plasma fibrinogen level after receiving short-term chemotherapy and shorter overall survival (OS). Conclusion: 1) This study shows high plasma fibrinogen concentration is associated with lymph nodes or distant organ metastases in lung cancer. 2) Furthermore, our results indicate a significant relevance between high pre-treatment plasma fibrinogen concentration and poor prognosis in patients with lung cancer. 3) In addition, we find that the patients with a low plasma fibrinogen level will have a shorter OS if the plasma fibrinogen level increases signific","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"42 1","pages":"14-21"},"PeriodicalIF":0.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78100251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}